Business Description
Waverley Pharma Inc
NAICS : 325412
SIC : 3741
ISIN : CA94357L1058
Compare
Compare
Traded in other countries / regions
WAVE.Canada5GZ.Germany IPO Date
2017-04-27Description
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Capecitabine and Temozolomide, among others.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.03 | |||||
| Equity-to-Asset | 0.09 | |||||
| Debt-to-Equity | 5.93 | |||||
| Debt-to-EBITDA | -1.61 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -7.23 | |||||
| Beneish M-Score | -4.82 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.1 | |||||
| 3-Year EBITDA Growth Rate | 27.3 | |||||
| 3-Year EPS without NRI Growth Rate | 20.6 | |||||
| 3-Year FCF Growth Rate | 46.4 | |||||
| 3-Year Book Growth Rate | -27.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.61 | |||||
| 9-Day RSI | 53.95 | |||||
| 14-Day RSI | 55.04 | |||||
| 12-1 Month Momentum % | 40 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.17 | |||||
| Quick Ratio | 0.12 | |||||
| Cash Ratio | 0.02 | |||||
| Days Inventory | 98.1 | |||||
| Days Sales Outstanding | 94.51 | |||||
| Days Payable | 644.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -34.01 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 29.83 | |||||
| Operating Margin % | -199.82 | |||||
| Net Margin % | -202.21 | |||||
| FCF Margin % | -134.07 | |||||
| ROE % | -139.06 | |||||
| ROA % | -44.58 | |||||
| ROIC % | -39.43 | |||||
| ROCE % | -130.29 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.5 | |||||
| PB Ratio | 8.75 | |||||
| EV-to-EBIT | -2.92 | |||||
| EV-to-EBITDA | -4.24 | |||||
| EV-to-Revenue | 5.53 | |||||
| EV-to-FCF | -4.12 | |||||
| Earnings Yield (Greenblatt) % | -34.36 | |||||
| FCF Yield % | -38.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Waverley Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 0.543 | ||
| EPS (TTM) (C$) | -0.024 | ||
| Beta | 0.45 | ||
| Volatility % | 177.72 | ||
| 14-Day RSI | 55.04 | ||
| 14-Day ATR (C$) | 0.002441 | ||
| 20-Day SMA (C$) | 0.0345 | ||
| 12-1 Month Momentum % | 40 | ||
| 52-Week Range (C$) | 0.015 - 0.04 | ||
| Shares Outstanding (Mil) | 54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Waverley Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Waverley Pharma Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Waverley Pharma Inc Frequently Asked Questions
What is Waverley Pharma Inc(TSXV:WAVE)'s stock price today?
The current price of TSXV:WAVE is C$0.04. The 52 week high of TSXV:WAVE is C$0.04 and 52 week low is C$0.02.
When is next earnings date of Waverley Pharma Inc(TSXV:WAVE)?
The next earnings date of Waverley Pharma Inc(TSXV:WAVE) is .
Does Waverley Pharma Inc(TSXV:WAVE) pay dividends? If so, how much?
Waverley Pharma Inc(TSXV:WAVE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers